Company: CSTL
Filing Date: 2025-11-03
Form Type: 10-Q
Source: 0001628280-25-048254
Chunk: 42

Company: CASTLE BIOSCIENCES INC
Filing Date: 2025-11-03
Form: 10-Q
Item: Item 1
Chunk 42
---
Grand TotalQ1 20258,621 4,375 926 13,922 470 7,432 2,578 24,402 Q2 20259,981 4,762 1,166 15,909 468 9,170 1,027 26,574 Q3 202510,459 4,186 1,151 15,796 436 10,609 — 26,841 For the nine months ended September 30, 202529,061 13,323 3,243 45,627 1,374 27,211 3,605 77,817 Q1 20248,384 3,577 998 12,959 422 3,429 4,078 20,888 Q2 20249,585 4,277 1,099 14,961 456 4,782 4,903 25,102 Q3 20249,367 4,195 933 14,495 397 6,073 5,045 26,010 For the nine months ended September 30, 202427,336 12,049 3,030 42,415 1,275 14,284 14,026 72,000 Q4 20248,672 4,299 879 13,850 424 6,672 3,125 24,071 For year ended December 31, 202436,008 16,348 3,909 56,265 1,699 20,956 17,151 96,071 

(1)The IDgenetix test was discontinued effective May 2025.

For the three and nine months ended September 30, 2025, our test report volume increased by 3.2% and 8.1%, respectively, compared to the same period in 2024. Our dermatologic test report volume increased by 9.0% and 7.6% for the three and nine months ended September 30, 2025, respectively, compared to the prior period in 2024, largely driven by continued growth from DecisionDx-Melanoma and DecisionDx-SCC tests. TissueCypher increased by 74.7% and 90.5%, respectively, for the three and nine months ended